TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs [Yahoo! Finance]
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: Yahoo! Finance
analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of cardiovascular device innovation. Its royalty-based model is anchored by two key programs: AVIM for hypertension and Virtue SAB for atherosclerotic disease, both of which target massive market gaps. With blue-chip partners and high-margin potential, the company is approaching critical data and commercialization milestones that could prove transformative. The company is currently advancing two high-impact pivotal programs. Enrollment officially initiated for the Virtue Trial as of Q3 2025, which is a US registrational study comparing Virtue SAB head-to-head against the commercially available AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis. Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) remains in full operational control of this trial, with enrollment completion targeted for mid-2027. Simultane
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by HaemoneticsGlobeNewswire
- Orchestra BioMed (NASDAQ:OBIO) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at TD Cowen. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.MarketBeat
OBIO
Sec Filings
- 1/12/26 - Form 8-K
- 1/2/26 - Form 4
- 1/2/26 - Form 4
- OBIO's page on the SEC website